| Find Sources And More: NSRX Website. NSRX Presentation. -----
5 Potential Catalysts Put (NYSE American: NSRX) In The Spotlight Monday
1.) NSRX Has A Really Low Float (Volatility Potential May Be Substantial).
Sporting a float of roughly 3.89Mn shares, according to Yahoo Finance, the potential for heightened volatility appearing quickly should not be dismissed.
2.) An Analyst Provides A Massive $22 Price Target (Over 325% Potential Upside).
A Laidlaw & Company analyst has tagged NSRX with a significant $22 target.
That target provides NSRX with a potential upside of 325+% from its closing valuation Friday.
Here are some highlights from the report:
We are initiating coverage on Nasus Pharma with a ... 12-month $22 price target. NSRX is a mid-clinical stage biotech/specialty pharma company focusing on the development of NS-002, a well differentiated powder-based intranasal anaphylaxis treatment.
Supported by robust clinical data, a second Phase II study will start in 4Q25, and if positive, a pivotal study could start in mid-2026 with topline readout by YE26.
The recently reported NS-002 in anaphylaxis Phase II study showed robust outcomes in all measured metrics, especially the critical ones of Cmax, Tmax, T100pg/ml and percentage of patients with time taken to reach 100pg when compared with EpiPen.
3.) Nasus Pharma To Showcase Promising NS002 Clinical Data Advancements Globally.
Nasus Pharma Ltd. announced it will present topline results from its Phase 2 repeated-dose clinical study of NS002, its innovative intranasal epinephrine powder.
This product aims to deliver life-saving treatment for anaphylaxis through a needle-free, fast-acting nasal route.
The company will host a conference call and webcast on March 16, 2026, to discuss findings.
The event highlights Nasus’s commitment to advancing emergency medicine solutions, offering a safer, more accessible alternative to traditional injectable epinephrine.
4.) Nasus Pharma Reports Exceptional NS002 Interim Phase Two Results.
Nasus Pharma shared encouraging interim data from its Phase 2 clinical study of NS002, showing faster absorption and higher peak epinephrine levels than EpiPen®.
91% percent of participants achieved optimal plasma thresholds within five minutes.
NS002 was well-tolerated with no serious adverse events.
These results position NS002 as a strong, needle-free alternative for rapid anaphylaxis treatment.
The company expects final Phase 2 data soon and plans to launch a pivotal study by year-end, reinforcing its leadership in intranasal emergency drug delivery innovation.
5.) Nasus Pharma Strengthens Growth And Innovation Through Transformative 2025 Achievements.
Nasus Pharma's CEO Dan Teleman’s 2025 shareholder letter highlighted a breakthrough year for Nasus Pharma.
The company made major progress developing NS002, its intranasal epinephrine powder, following successful early clinical trials and a $10Mn IPO.
Partnerships with Aptar enhance regulatory and manufacturing readiness, while Health Canada authorized NS002’s Phase 2 study.
Nasus plans multiple milestones in 2026, including Phase 2 topline results and pivotal study initiation.
These advancements underline Nasus Pharma’s strong momentum toward market introduction of life-saving, user-friendly nasal treatments and expansion of its innovative Nasax-based pipeline. -----
We're initiating coverage on Nasus Pharma Ltd. (NYSE American: NSRX).
Updates will be heading your way soon. Keep your eyes peeled.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 03/16/2026 and ending on 03/16/2026 to publicly disseminate information about (NSRX:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (NSRX:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/nsrx-xkxr2/#details | 
Tidak ada komentar:
Posting Komentar